Literature DB >> 23480577

Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes.

Maria Boddi1, Roberto Tarquini, Marco Chiostri, Fabio Marra, Serafina Valente, Cristina Giglioli, Gian F Gensini, Rosanna Abbate.   

Abstract

BACKGROUND: Growing evidence was collected that non-alcoholic liver fatty disease (NAFLD) is a risk factor for coronary atherosclerosis in terms of angiographic appearance, but its involvement in acute coronary syndromes is still debated. We investigated the prevalence and severity of NAFLD in non-diabetic patients admitted for ST-segment elevation myocardial infarction (STEMI) and its association with multi-vessel coronary artery disease (CAD).
MATERIALS AND METHODS: Ninety-five consecutive non-diabetic patients admitted to cardiac ICU for STEMI were studied by ultrasound within 72 h from admission. NAFLD was graded according to a semi-quantitative severity score as mild (score < 3) or moderate-severe (> 3 score). Prevalence of cardiovascular (CV) risk factors, atherosclerotic burden markers and metabolic syndrome (MS) was investigated.
RESULTS: The overall prevalence of NAFLD was 87%. Forty-eight patients showed moderate-severe NAFLD (SFLD). Thirty-five patients showed mild NAFLD (MLFD group) and 12 patients had no NAFLD. Patients with SFLD were younger and showed higher prevalence of multi-vessel CAD (i.e. > 2) than patients with mild MFLD (P < 0·01). Total cholesterol, triglycerides, body mass index and waist circumference were higher and HDL lower in SFLD than MFLD patients. About 50% of all NAFLD patients did not have MS. MS prevalence was higher in SFLD than MLFD patients (P < 0·05) and among MS components, waist circumference and triglyceride levels showed the strongest association with SFLD (P < 0·05). At logistic regression analysis, SFLD was independently associated with a three-fold risk of multi-vessel CAD.
CONCLUSIONS: In non-diabetic patients admitted for STEMI NAFLD prevalence was very high. Severe NAFLD independently increased the risk for multi-vessel CAD associated to CV events.
© 2013 The Authors. European Journal of Clinical Investigation © 2013 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Year:  2013        PMID: 23480577     DOI: 10.1111/eci.12065

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

1.  Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome.

Authors:  Jasbir Makker; Hassan Tariq; Jonathan N Bella; Kishore Kumar; Chukwunonso Chime; Harish Patel; Muhammad Umar Kamal; Danial Shaikh; Vamshidhar Vootla; Bharat Bajantri; Umut Gomceli; Mohammad Alshelleh; Richard Peralta; Aiyi Zhang; Sridhar Chilimuri
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

2.  Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study.

Authors:  Alina M Allen; Terry M Therneau; Kristin C Mara; Joseph J Larson; Kymberly D Watt; Sharonne N Hayes; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2019-11       Impact factor: 10.864

3.  Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI.

Authors:  Flavio Giuseppe Biccirè; Francesco Barillà; Emanuele Sammartini; Edoardo Maria Dacierno; Gaetano Tanzilli; Daniele Pastori
Journal:  Clin Res Cardiol       Date:  2022-08-11       Impact factor: 6.138

Review 4.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

Review 6.  Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations.

Authors:  Alexander J Kovalic; George Cholankeril; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-03

7.  Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka.

Authors:  Nilanka Perera; Jegarajah Indrakumar; Waruni Vijitha Abeysinghe; Vihangi Fernando; W M C K Samaraweera; Jayamal Sanjaya Lawrence
Journal:  BMC Cardiovasc Disord       Date:  2016-02-12       Impact factor: 2.298

8.  "Non alcoholic fatty liver disease and eNOS dysfunction in humans".

Authors:  Marcello Persico; Mario Masarone; Antonio Damato; Mariateresa Ambrosio; Alessandro Federico; Valerio Rosato; Tommaso Bucci; Albino Carrizzo; Carmine Vecchione
Journal:  BMC Gastroenterol       Date:  2017-03-07       Impact factor: 3.067

Review 9.  A Review of Cardiovascular Toxicity of Microcystins.

Authors:  Linghui Cao; Isaac Yaw Massey; Hai Feng; Fei Yang
Journal:  Toxins (Basel)       Date:  2019-08-30       Impact factor: 4.546

10.  Nonalcoholic fatty liver disease, a potential risk factor of non-specific ST-T segment changes: data from a cross-sectional study.

Authors:  Li Xiao; Tao Bai; Junchao Zeng; Rui Yang; Ling Yang
Journal:  PeerJ       Date:  2020-05-13       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.